- Biotechnology
- Healthcare
-
1.29
EPS
-
55.62
P/E
-
11.3B
MARKET CAP
-
0.45%
DIV YIELD
Company Overview
614 MCKINLEY PL N E,MINNEAPOLIS MN 55413,6123798854
CEO
Mr. Kim Kelderman
Employess
3100
Sector
Healthcare
Industry
Biotechnology
Website
https://www.bio-techne.com
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Next Earnings Date
Oct. 29, 2024
Ex Dividends date
Aug. 30, 2024
Dividend Date
Aug. 19, 2024
YTD Performance
-6.44%
Fiscal Year End
06-30
IPO Date
1989-02-09
Growth Rates
| (avg. rate of change) | 10 years | 5 years | 3 years | 1 year |
|---|---|---|---|---|
| Sales/Revenue | 12.47% | 10.17% | 7.58% | 1.97% |
| EPS | 3.62% | 10.83% | 5.55% | -40.88% |
| Equity | 10.03% | 12.16% | 9.60% | 5.20% |
| Cash | -7.15% | 8.51% | -8.65% | -15.94% |
| Return On Capital (ROIC) | 8.50% | 8.29% | 10.32% | 7.79% |
Debt
| year (millions) | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Short Term Debt | 12.9 | 11.2 | 24.4 | 24.1 | 22 |
| Long Term Debt | 319 | 444 | 302 | 396 | 411 |
| LT Finance Leases | 87.6 | 105 | 70.1 | 79.2 | 76.8 |
| Shares Outstanding | 158 | 157 | 157 | 155 | 153 |
| Market Cap | 11,300 | 12,800 | 13,600 | 17,400 | 10,100 |
Price
News
ODDITY TECH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
1 monthNEW ORLEANS , Aug. 9, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd. ("Oddity" or the "Company") (NasdaqGM: ODD), if they purchased the Company's securities between July 19, 2023 and May 20, 2024, inclusive (the "Class Period").
prnewswire.com
ODDITY TECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
1 monthKahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd.
accesswire.com
ODDITY TECH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
1 monthNEW ORLEANS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd. (“Oddity” or the “Company”) (NasdaqGM: ODD), if they purchased the Company's securities between July 19, 2023 and May 20, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of New York.
globenewswire.com
ODDITY TECH REPORTS RECORD SECOND QUARTER RESULTS, RAISES OUTLOOK
1 monthRecord second quarter net revenue of $193 million, up 27% year-over-year Record second quarter adjusted EBITDA of $62 million, up 49% year-over-year Record second quarter net income of $45 million, up 52% year-over-year, and record second quarter adjusted net income of $51 million, up 58% year-over-year Record first half net operating cash flow of $105 million and free cash flow of $104 million Announces Ido Bachelet as Chief Science Officer NEW YORK , Aug 7, 2024 /PRNewswire/ -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced its financial results for the second quarter ended June 30, 2024.
prnewswire.com
Techne (TECH) Misses Q4 Earnings and Revenue Estimates
1 monthTechne (TECH) came out with quarterly earnings of $0.49 per share, missing the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.55 per share a year ago.
zacks.com
Bio-Techne meets Q4 profit estimates on demand for its diagnostics products
1 monthBio-Techne reported fourth-quarter profit in line with estimates on Wednesday as growth in the diagnostics and genomics unit offset weakness in its protein sciences unit.
reuters.com
BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS
1 monthMINNEAPOLIS , Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2024. Fourth Quarter FY2024 Highlights Fourth quarter organic revenue increased by 1% (2% reported) to $306.1 million.
prnewswire.com
BIO-TECHNE DECLARES DIVIDEND
1 monthMINNEAPOLIS , Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2024. The quarterly dividend will be payable August 30, 2024, to all common shareholders of record on August 19, 2024.
prnewswire.com
ODDITY TECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
1 monthNEW ORLEANS, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd. (“Oddity” or the “Company”) (NasdaqGM: ODD), if they purchased the Company's securities between July 19, 2023 and May 20, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of New York.
globenewswire.com
3 Genomics Stocks That May Transform Personalized Medicine
1 monthWhen the human genome was fully sequenced in 2003, the prospects of genetic medicine ushered in a new era of human health. Today, scientists and drug developers have a better understanding of the genetic drivers of disease than ever before.
investorplace.com
ODDITY TECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
1 monthNEW ORLEANS, LA / ACCESSWIRE / August 5, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd.
accesswire.com
ODDITY TECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
2 monthsNEW ORLEANS , Aug. 2, 2024 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd.
prnewswire.com